ESLAW
Estrella Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.08
+3.33%Income statement
| Metric | TTM | 2025 | 2024 | 2024 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 7.0M | 10.2M | 6.4M | 4.1M | 10.5M |
| SG&A Expense | 2.8M | 2.8M | 2.4M | 3.2M | 663.2K |
| General & Admin Expense | 2.8M | 2.8M | 2.4M | 3.2M | 663.2K |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 9.8M | 13.1M | 8.8M | 7.3M | 11.1M |
| Cost and Expenses | 9.8M | 13.1M | 8.8M | 7.3M | 11.1M |
| Operating Income (EBIT) | (9.8M) | (13.1M) | (8.8M) | (7.3M) | (11.1M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | (222.1K) | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (10.0M) | (13.1M) | (8.8M) | (7.3M) | (11.1M) |
| Income Tax Expense | (25.00) | 838.00 | 1.7K | 1.6K | — |
| Bottom Line | |||||
| Net Income | (10.0M) | (13.1M) | (8.8M) | (7.3M) | (11.1M) |
| Earnings from Cont. Ops | (10.0M) | (13.1M) | (8.8M) | (7.3M) | (11.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.0M) | (13.1M) | (8.8M) | (7.3M) | (11.1M) |
| Per Share | |||||
| Basic EPS | ($0.25) | ($0.35) | ($0.24) | ($0.21) | ($0.32) |
| Diluted EPS | ($0.25) | ($0.35) | ($0.24) | ($0.21) | ($0.32) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 43.0M | 36.8M | 36.7M | 35.2M | 35.2M |
| Diluted Shares Outstanding | 43.0M | 36.8M | 36.7M | 35.2M | 35.2M |
| Profitability Metrics | |||||
| EBITDA | (9.8M) | (13.1M) | (8.8M) | (7.3M) | (11.1M) |
| D&A | — | — | — | — | — |
| EBIT | (9.8M) | (13.1M) | (8.8M) | (7.3M) | (11.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026